HCM
ACRS icon

Highbridge Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Highbridge Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-300,000
Closed -$5.26M – 866
2018
Q1 		$5.26M Buy
300,000
+100,000
+50% +$2.12M 0.08% 275
2017
Q4 		$4.93M Buy
200,000
+100,000
+100% +$2.44M 0.09% 269
2017
Q3 		$2.58M Buy
+100,000
New +$2.68M 0.04% 394
2017
Q1 		– Sell
-13,105
Closed -$355K – 1408
2016
Q4 		$355K Buy
+13,105
New +$334K 0.01% 898

Other funds holding ACRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Highbridge Capital Management's ACRS Position: Q2 2018 in Review

Highbridge Capital Management sold out of Aclaris Therapeutics (ACRS) in Q2 2018, closing a stake of 300,000 shares — an estimated $5.26M sold.

Highbridge Capital Management first reported a position in ACRS in Q4 2016 and held it in 4 quarters. The position peaked at $5.26M in Q1 2018. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2018.

  • Highbridge Capital Management reported no remaining Aclaris Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Highbridge Capital Management sold 300,000 Aclaris Therapeutics shares in Q2 2018, an estimated $5.26M.
  • Highbridge Capital Management first reported a position in Aclaris Therapeutics in Q4 2016 and held it in 4 quarters.
  • Highbridge Capital Management's Aclaris Therapeutics position peaked at $5.26M in Q1 2018.
  • 96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2018.

Based on Highbridge Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.